✨ Free AI Report
Amphastar Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Amphastar Pharmaceuticals, Inc.
Research Preview

Amphastar Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Amphastar Pharmaceuticals develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products. The company is undergoing a significan...

Analyst-debate audio for Amphastar Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Amphastar Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Amphastar Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Amphastar is a transitional story with asymmetric risk-reward: strong long-term pipeline potential offset by near-term headwinds...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals / Complex Generics and Proprietary Injectables
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Amphastar Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Amphastar Pharmaceuticals, Inc. Overview

Pro stress-test →

Amphastar Pharmaceuticals develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products. The company is undergoing a significant strategic pivot from legacy generic products toward a diversified portfolio of proprietary and biosimilar products, while facing near-term pressure from declining legacy generics and margin compression.

Strategic Profile

Pro stress-test →

The company projects that proprietary and biosimilar products will represent 85% of its pipeline by 2026, reflecting management's conviction that the company's future lies in complex, differentiated therapies rather than commodity generics. Amphastar's vertically integrated manufacturing capabilities and technical expertise in peptides, inhalation products, and biosimilars provide a competitive advantage, offering quality control advantages and potentially faster development timelines.

Competitive Landscape

Pro stress-test →

Amphastar competes in the injectable and inhalation pharmaceuticals space against larger competitors including Eli Lilly, Bristol-Myers Squibb, and various generic manufacturers. The company differentiates through technical expertise in complex formulations and vertical integration. Competitive pressures from generic glucagon, epinephrine, and phytonadione are expected to offset new product growth.

Industry Context

Amphastar Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Complex Generics and Proprietary Injectables.

Key facts

Founded: 2004 · Headquarters: Rancho Cucamonga, California · Revenue: $719.9 million (FY2025)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Amphastar Pharmaceuticals, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Amphastar Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Glucagon genericsCompetitive generic pressure on Amphastar's legacy products→Epinephrine/Naloxone genericsLong-established competition in emergency injectable space→BAQSIMI direct competitorProprietary glucagon alternative for diabetes management→

Compare Amphastar Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Amphastar Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Complex Generics and Proprietary Injectables. See how the rest of the sector scores on the Cyborg framework.

Top companies in Specialty Pharmaceuticals by Cyborg Score

Browse Specialty Pharmaceuticals / Complex Generics and Proprietary Injectables research →
NEW · MCP server

Ask your AI assistant about Amphastar Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Amphastar Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Amphastar Pharmaceuticals, Inc. do this quarter?”
“Is Amphastar Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Amphastar Pharmaceuticals, Inc. do?+
Amphastar Pharmaceuticals develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products. The company is undergoing a significan...
What is Amphastar Pharmaceuticals, Inc.'s Cyborg Score?+
Amphastar Pharmaceuticals, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Amphastar Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Glucagon generics, Epinephrine/Naloxone generics, BAQSIMI direct competitor. The full competitive landscape is in the AskCyborg report.
How can I get the full Amphastar Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Amphastar Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Amphastar Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Catalyst Pharmaceuticals, Inc.7Achieve Life Sciences, Inc.7Assertio Holdings, Inc.7Viatris Inc.7Xeris Biopharma Holdings, Inc.6Allergy Therapeutics PLC6Eagle Pharmaceuticals Inc.6Santhera Pharmaceuticals Holding AG6Supernus Pharmaceuticals, Inc.5Animalcare Group PLCTop companies in Specialty Pharmaceuticals by Cyborg Score